Edesa Biotech is trading at $4.73 (+6.29%) following Velan Capital’s disclosure of a 9.99% stake with warrant exposure after purchasing shares in the offering.
- The company is rebounding from selling pressure tied to its $25 million public offering.
- The financing was priced at $5.50 per share, supporting investor confidence despite dilution concerns.
- Biotech-sector strength, with XBI up 2.06%, provides additional support, though the investor disclosure appears to be the primary catalyst.